130. 先天性無痛無汗症 ［臨床試験数：1，薬物数：9（DrugBank：7），標的遺伝子数：4，標的パスウェイ数：34］
Searched query = "Congenital insensitivity to pain with anhydrosis", "CIPA", "Hereditary sensory and autonomic neuropathy type IV", "HSAN4", "Hereditary sensory and autonomic neuropathy type V", "HSAN5"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03070470 | March 14, 2017 | 16 December 2017 | CiPA Phase 1 ECG Biomarker Validation Study | Comprehensive in Vitro Proarrhythmia Assay (CiPA) Clinical Phase 1 ECG Biomarker Validation Study (CiPA Phase 1 ECG Biomarker Study) | Drug-induced QT Prolongation;Pharmacokinetics;Pharmacodynamics | Drug: Ranolazine;Drug: Verapamil;Drug: Lopinavir / Ritonavir;Drug: Chloroquine;Drug: Placebo;Drug: Dofetilide and Diltiazem | Food and Drug Administration (FDA) | Spaulding Clinical Research LLC | Not recruiting | 18 Years | 50 Years | All | 57 | Phase 1 | United States |